Gevo, Inc. : Gevo Wins Patent Suit in Delaware Court

             Gevo, Inc. : Gevo Wins Patent Suit in Delaware Court

Butamax admits Gevo does not infringe and trial not needed

ENGLEWOOD, Colo. - March 21, 2013 - Gevo, Inc. (NASDAQ: GEVO), announced today
that a judgment  of non-infringement will  be entered for  Gevo following  the 
acknowledgment by Butamax Advanced Biofuels  LLC (Butamax) that Gevo does  not 
infringe Butamax's asserted patents  under the Court's  construction of a  key 
claim term in Butamax's Patent Nos.  7,851,188 and 7,993,889. As a result  of 
this victory, a judgment of non-infringement  will be entered in Gevo's  favor 
and the trial scheduled for April 1^st will no longer take place.

"This is an outstanding victory for  Gevo," noted Brett Lund, EVP and  General 
Counsel for Gevo. "We  have consistently maintained that  we do not  infringe 
any Butamax  patents  and  Butamax's  concession  resoundingly  validates  our 
position."

The judgment of non-infringement comes on  the heels of the Court's  important 
claim  construction  determination  which  held  that  Butamax's  Patent  Nos. 
7,851,188 and 7,993,889 require the use of an "NADPH-dependent" KARI. Butamax
conceded that it could not establish that Gevo's KARI is NADPH-dependent.

"Gevo continues to  demonstrate that  it does not  infringe Butamax's  patents 
because Gevo created an NADH-dependent  KARI enzyme that enables Gevo's  yeast 
strains to produce isobutanol at much greater efficiencies than strains  using 
the NADPH-dependent enzymes claimed by Butamax," said Lund. "We fully expect
Butamax will appeal to the Federal Circuit, but we are confident in the merits
of our case."

In addition to granting a judgment of non-infringement, the Court  invalidated 
Butamax's  patent  claims  for  the  deletion  of  PDC.  PDC  is  the  enzyme 
responsible  for  making  ethanol  and  its  deletion  is  required  for   the 
commercially viable  production of  isobutanol. Gevo's  patents covering  the 
deletion of PDC and the use of AFT  are set for trial in August of this  year, 
where Gevo is suing Butamax for patent infringement.

Gevo will host a conference call on Thursday, Mar. 21, 2013 at 11:30 a.m. EDT
(9:30 a.m. MDT) to discuss this significant win.

To participate in the conference call, please dial 1-866-825-1709 (inside the
US) or 1- 617-213-8060 (outside the US) and reference the access code
89618382. The presentation will be available via a live webcast at:
http://www.media-server.com/m/acs/5d3c8682f834060fbfe1eed178c48342

A replay of the  call will be  available two hours  after the conference  call 
ends on Oct.  30, 2012  until Midnight  EST on Nov.  30, 2012.  To access  the 
replay, please dial 1-888-286-8010 (inside the US) or 1-617-801-6888  (outside 
the US) and reference the access  code 81289891. The archived webcast will  be 
available for 30 days in the  Investor Relations section of Gevo's website  at 
www.gevo.com.

About Gevo

Gevo is a leading renewable chemicals and next-generation biofuels company.
Gevo's patent-protected, capital-light business model converts existing
ethanol plants into biorefineries to make isobutanol. This versatile chemical
can be directly integrated into existing chemical and fuel products to deliver
environmental and economic benefits. Gevo started up its first commercial
isobutanol facility in Luverne, Minn., and has a marquee list of partners
including Coca-Cola, Sasol, and LANXESS, among others. Gevo is committed to a
sustainable bio-based economy that meets society's needs for plentiful food
and clean air and water. For more information, visit www.gevo.com.

Forward-Looking Statements

Certain statements  in  this  press release  may  constitute  "forward-looking 
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995.  These forward-looking  statements include  statements that  are  not 
purely statements of historical fact, and  can sometimes be identified by  our 
use of  terms  such  as  "intend,"  "expect,"  "plan,"  "estimate,"  "future," 
"strive" and similar words. These  forward-looking statements are made on  the 
basis of the current beliefs,  expectations and assumptions of the  management 
of Gevo and are  subject to significant risks  and uncertainty. Investors  are 
cautioned not to place undue reliance on any such forward-looking  statements. 
All such forward-looking statements speak only  as of the date they are  made, 
and the company undertakes no obligation to update or revise these statements,
whether as a result of new  information, future events or otherwise.  Although 
the company believes that the expectations reflected in these  forward-looking 
statements  are   reasonable,  these   statements  involve   many  risks   and 
uncertainties that may cause actual results to differ materially from what may
be expressed or  implied in  these forward-looking statements.  For a  further 
discussion of  risks and  uncertainties  that could  cause actual  results  to 
differ from those expressed  in these forward-looking  statements, as well  as 
risks relating to the business of Gevo in general, see the risk disclosures in
the Annual Report on Form 10-K of  Gevo for the year ended December 31,  2011, 
as amended, and in subsequent reports on Forms 10-Q and 8-K and other  filings 
made with the SEC by Gevo.

                                     ###

Media Contact:

Josh Laster

Gibbs & Soell for Gevo

T: (212) 697-2600

jlaster@gibbs-soell.com

Investor Contact:

Chelsea DeLong

PR & Marketing Coordinator

T: (303) 588-6306

cdelong@gevo.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Gevo, Inc. via Thomson Reuters ONE
HUG#1687073